Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/1822/24037 |
Resumo: | INTRODUCTION: Monocarboxylate transporter 2 (MCT2) is a transmembrane protein involved in the transport of monocarboxylates such as pyruvate and lactate. In a previous study we described overexpression of MCT2 in prostate carcinoma raising the hypothesis of using MCT2 as a possible biomarker in prostate cancer. With the present study we aimed to compare the pattern of expression of MCT2 and alpha-methylacyl-CoA racemase (AMACR), in prostate carcinoma, PIN lesions, non-neoplastic prostate tissue, and normal prostate and compare their sensitivity and specificity. Also, we wanted to evaluate the value of using MCT2 in combination with AMACR and the negative markers 34βE12 or p63 to detect prostate cancer. METHODS: A total of 349 cases, including prostate carcinoma, non-neoplastic prostate tissue and PIN lesions, from radical prostatectomies were examined by immunohistochemistry for AMACR, MCT2, p63, and 34βE12, using tissue microarrays (TMAs). Normal prostate from radical cystoprostatectomy was also studied. RESULTS: Our study revealed that MCT2, similarly to AMACR, was consistently expressed in prostate cancer regardless of the Gleason score. In combination with AMACR and p63 or 34βE12, MCT2 helped to improve the diagnosis of prostate carcinoma. Also, overexpression of MCT2 as well as AMACR in PIN lesions may indicate the involvement of these two proteins in prostate cancer initiation. CONCLUSIONS: We provided evidence for the presence of MCT2 in prostate cancer, selectively labeling malignant glands. Importantly, assessment of MCT2 together with AMACR, along with the negative markers, highly increases the accuracy in prostate cancer diagnosis. |
id |
RCAP_bb177fb3c328b292f7ca275392a2b878 |
---|---|
oai_identifier_str |
oai:repositorium.sdum.uminho.pt:1822/24037 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancerAlpha-methylacyl-CoA racemaseCancer biomarkersProstate cancer diagnosisScience & TechnologyINTRODUCTION: Monocarboxylate transporter 2 (MCT2) is a transmembrane protein involved in the transport of monocarboxylates such as pyruvate and lactate. In a previous study we described overexpression of MCT2 in prostate carcinoma raising the hypothesis of using MCT2 as a possible biomarker in prostate cancer. With the present study we aimed to compare the pattern of expression of MCT2 and alpha-methylacyl-CoA racemase (AMACR), in prostate carcinoma, PIN lesions, non-neoplastic prostate tissue, and normal prostate and compare their sensitivity and specificity. Also, we wanted to evaluate the value of using MCT2 in combination with AMACR and the negative markers 34βE12 or p63 to detect prostate cancer. METHODS: A total of 349 cases, including prostate carcinoma, non-neoplastic prostate tissue and PIN lesions, from radical prostatectomies were examined by immunohistochemistry for AMACR, MCT2, p63, and 34βE12, using tissue microarrays (TMAs). Normal prostate from radical cystoprostatectomy was also studied. RESULTS: Our study revealed that MCT2, similarly to AMACR, was consistently expressed in prostate cancer regardless of the Gleason score. In combination with AMACR and p63 or 34βE12, MCT2 helped to improve the diagnosis of prostate carcinoma. Also, overexpression of MCT2 as well as AMACR in PIN lesions may indicate the involvement of these two proteins in prostate cancer initiation. CONCLUSIONS: We provided evidence for the presence of MCT2 in prostate cancer, selectively labeling malignant glands. Importantly, assessment of MCT2 together with AMACR, along with the negative markers, highly increases the accuracy in prostate cancer diagnosis.This work was supported by the FCT grant ref.PTDC/SAUMET/113415/2009 under the scope of ‘Programa Operacional Tematico Factores de Competitividade’’ (COMPETE) of ‘‘Quadro Comunitario de Apoio III’’ and co-financed by ‘‘Fundo Comunitario Europeu’’ FEDER. N.P.G. received fellowship from the Portuguese Foundation for Science and Technology (FCT), ref. FRH/BD/61027/2009.Wiley-BlackwellUniversidade do MinhoPértega-Gomes, NelmaVízcaíno, RamónGouveia, CarlosJerónimo, CarmenHenrique, Rui M.Lopes, CarlosBaltazar, Fátima20132013-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/1822/24037engPértega-Gomes, N., Vizcaíno, J. R., Gouveia, C., Jerónimo, C., Henrique, R. M., Lopes, C. and Baltazar, F. (2013), Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate, 73: 763–769. doi: 10.1002/pros.226200270-413710.1002/pros.2262023192371http://onlinelibrary.wiley.com/doi/10.1002/pros.22620/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-21T12:44:18Zoai:repositorium.sdum.uminho.pt:1822/24037Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T19:41:58.401251Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer |
title |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer |
spellingShingle |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer Pértega-Gomes, Nelma Alpha-methylacyl-CoA racemase Cancer biomarkers Prostate cancer diagnosis Science & Technology |
title_short |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer |
title_full |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer |
title_fullStr |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer |
title_full_unstemmed |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer |
title_sort |
Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer |
author |
Pértega-Gomes, Nelma |
author_facet |
Pértega-Gomes, Nelma Vízcaíno, Ramón Gouveia, Carlos Jerónimo, Carmen Henrique, Rui M. Lopes, Carlos Baltazar, Fátima |
author_role |
author |
author2 |
Vízcaíno, Ramón Gouveia, Carlos Jerónimo, Carmen Henrique, Rui M. Lopes, Carlos Baltazar, Fátima |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade do Minho |
dc.contributor.author.fl_str_mv |
Pértega-Gomes, Nelma Vízcaíno, Ramón Gouveia, Carlos Jerónimo, Carmen Henrique, Rui M. Lopes, Carlos Baltazar, Fátima |
dc.subject.por.fl_str_mv |
Alpha-methylacyl-CoA racemase Cancer biomarkers Prostate cancer diagnosis Science & Technology |
topic |
Alpha-methylacyl-CoA racemase Cancer biomarkers Prostate cancer diagnosis Science & Technology |
description |
INTRODUCTION: Monocarboxylate transporter 2 (MCT2) is a transmembrane protein involved in the transport of monocarboxylates such as pyruvate and lactate. In a previous study we described overexpression of MCT2 in prostate carcinoma raising the hypothesis of using MCT2 as a possible biomarker in prostate cancer. With the present study we aimed to compare the pattern of expression of MCT2 and alpha-methylacyl-CoA racemase (AMACR), in prostate carcinoma, PIN lesions, non-neoplastic prostate tissue, and normal prostate and compare their sensitivity and specificity. Also, we wanted to evaluate the value of using MCT2 in combination with AMACR and the negative markers 34βE12 or p63 to detect prostate cancer. METHODS: A total of 349 cases, including prostate carcinoma, non-neoplastic prostate tissue and PIN lesions, from radical prostatectomies were examined by immunohistochemistry for AMACR, MCT2, p63, and 34βE12, using tissue microarrays (TMAs). Normal prostate from radical cystoprostatectomy was also studied. RESULTS: Our study revealed that MCT2, similarly to AMACR, was consistently expressed in prostate cancer regardless of the Gleason score. In combination with AMACR and p63 or 34βE12, MCT2 helped to improve the diagnosis of prostate carcinoma. Also, overexpression of MCT2 as well as AMACR in PIN lesions may indicate the involvement of these two proteins in prostate cancer initiation. CONCLUSIONS: We provided evidence for the presence of MCT2 in prostate cancer, selectively labeling malignant glands. Importantly, assessment of MCT2 together with AMACR, along with the negative markers, highly increases the accuracy in prostate cancer diagnosis. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013 2013-01-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1822/24037 |
url |
http://hdl.handle.net/1822/24037 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Pértega-Gomes, N., Vizcaíno, J. R., Gouveia, C., Jerónimo, C., Henrique, R. M., Lopes, C. and Baltazar, F. (2013), Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate, 73: 763–769. doi: 10.1002/pros.22620 0270-4137 10.1002/pros.22620 23192371 http://onlinelibrary.wiley.com/doi/10.1002/pros.22620/pdf |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Wiley-Blackwell |
publisher.none.fl_str_mv |
Wiley-Blackwell |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799132970385145856 |